91 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
the external auditors' assessment of the appropriateness of the Company's auditing and accounting principles as applied in its financial reporting;
(y
20-F/A
2021 FY
REPCF
Replicel Life Sciences Inc.
12 Sep 22
Annual report (foreign) (amended)
6:17pm
these deficiencies. We intend to consider the results of our remediation efforts and related testing as part of our year-end 2022 assessment … to continue to update the documentation of our internal control processes, including formal risk assessment of our financial reporting processes
UPLOAD
REPCF
Replicel Life Sciences Inc.
23 Aug 22
Letter from SEC
12:00am
not performed an
audit of management's assessment of the effectiveness of internal
control over financial
reporting. Please clarify
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
4 Aug 22
Current report (foreign)
11:41am
.”
2 | Page
“An integrated approach to the evaluation of cell-delivery success is needed to improve the assessment of delivery efficacy and to allow
6-K
EX-99.2
nfb179ma768in
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
thgzbso5yrz
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.2
6ljn7ync
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
t7h2rox ypepn
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
20-F/A
bm0vutk irk2qnh
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.1
ckd9hi3xn8djk
13 Nov 20
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.2
qw7bgt86e1 txk8
27 Nov 19
Condensed Consolidated Interim Financial Statements
5:09pm
6-K
EX-99.1
hs5acp3lxqytiabx
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
v0wnz
24 Sep 19
Current report (foreign)
1:49pm
6-K
EX-99.1
q1u cpcrkgieuxli3s7
29 Aug 19
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
11:47am
6-K
EX-99.2
2d913hxb7btyt0qj2v
23 Aug 19
Condensed Consolidated Interim Financial Statements
3:47pm
6-K
EX-99.2
this7tud63c39z0kp
30 May 19
Condensed Consolidated Interim Financial Statements
4:20pm